Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$118.60 USD
+5.23 (4.61%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $118.59 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Price, Consensus and EPS Surprise
ABT 118.60 +5.23(4.61%)
Will ABT be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ABT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ABT
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?
ABT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Retain ABT Stock in Your Portfolio Now
ABT's New Trial on Advanced Heart Failure Outcomes Set to Boost Stock
HCA Healthcare Beats on Q3 Earnings, Reaffirms 2024 EPS View
Other News for ABT
What You Missed On Wall Street This Past Friday
Apple, Amazon, Chevron report quarterly beats: Morning Buzz
Abbott Laboratories (ABT) Shares Up 5.57% on Nov 1
Abbott (ABT) Surges with Strong Q3 Results and $7 Billion Buyback Plan
Reckitt and Abbott Shares Rally on Baby Formula Lawsuit Win